Investor
FCPM III SERVICES B.V.
CIK 0002013410 · filed 2026-05-15 · SEC filing
13F book
$722.2M
Positions
10
1 new · 1 sold
Largest name
40.8%
Newamsterdam Pharma Company
Est. mark
−$34.7M
Price effect on 9 names still held. Flow −$5.96M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Newamsterdam Pharma Company | — | 9.2M | $294.5M | 40.8% | −$28.2M | Held |
| Dyne Therapeutics, Inc. | DYN | 4.64M | $84.2M | 11.7% | −$6.64M | Cut−$22.7M |
| Vor Biopharma Inc. | VOR | 4.12M | $73.5M | 10.2% | $17.2M | Added$26.1M |
| Engene Holdings Inc | — | 9.63M | $65.6M | 9.1% | −$21.4M | Held |
| MapLight Therapeutics, Inc. | MPLT | 3.23M | $65.6M | 9.1% | $8.92M | Held |
| Galecto Inc | DMRA | 2.44M | $63.2M | 8.8% | — | New |
| Crescent Biopharma, Inc. | CBIO | 1.68M | $30.8M | 4.3% | $10.9M | Held |
| Replimune Group, Inc. | REPL | 2.81M | $21.5M | 3.0% | −$5.81M | Held |
| Bicycle Therapeutics Plc | BCYC | 3.47M | $16.1M | 2.2% | −$8.46M | Held |
| Engene Holdings Inc | — | 2.88M | $7.28M | 1.0% | −$1.24M | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.